Stay updated with breaking news from Clinical Trials Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
THURSDAY, Jan. 5, 2023 (HealthDay News) -- Lecanemab: It's an experimental medication that's been shown in trials to slow cognitive decline in people with Alzheimer’s disease.
FRIDAY, Jan. 6, 2023 (HealthDay News) -- The U.S. Food and Drug Administration on Friday approved a second Alzheimer's drug, lecanemab, despite reports of rare brain bleeds linked to use
FRIDAY, Jan. 6, 2023 (HealthDay News) -- The U.S. Food and Drug Administration on Friday approved a second Alzheimer's drug, lecanemab, despite reports of rare brain bleeds linked to use
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/tronc/N7GLCKRIKZGB3CCM3OQZG4GWTY.jpg)
THURSDAY, Jan. 5, 2023 (HealthDay News) -- Lecanemab: It’s an experimental medication that’s been shown in trials to slow cognitive decline in people with Alzheimer’s disease.
THURSDAY, Jan. 5, 2023 (HealthDay News) -- Lecanemab: It's an experimental medication that's been shown in trials to slow cognitive decline in people with Alzheimer’s disease.